RDGL VIVOS INC

Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India

Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India

Kennewick, WA, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL)

The Vivos Board granted authorization to form a wholly owned corporate subsidiary in India. Vivos Inc filed for the name of Vivos Scientific India LLP. Vivos is completing the steps remaining to obtain formal approvals from the Indian government.

“This demonstrates our long-term commitment to doing business in India and supports our long-term plan of establishing our first international manufacturing center for RadioGel and IsoPet, for expanding our developmental animal testing, and for commercially treating humans and animals in India.”

India is an important region for us, having initiated first in human trials, which we announced in December of 2024. We are actively pursuing DCGI (Drug Controller General of India) approval for additional expanded human trials in India. As we have previously stated, we believe our India trials are supportive of our IDE process with the FDA. Based on feedback from the FDA, as part of our IDE application process, our formal protocol for the next phase of human trials in India will include immediate post treatment PET full- body scans to further validate RadioGel’s safety profile.

Michael K. Korenko, Sc.D.

CEO, Vivos Inc.

Email:

Follow Vivos Inc. on X (Twitter): @VivosIncUSA

Learn more about RadioGel® and IsoPet® at

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, identified by terms such as “will,” “expects,” “plans,” “anticipates,” and “intends.” These statements involve risks and uncertainties that may cause actual results to differ materially, including challenges in executing business strategies, economic conditions, competition, regulatory changes, delays in clinic certifications, and other factors beyond Vivos Inc.’s control. For a detailed discussion of these risks, refer to the company’s filings with the Securities and Exchange Commission.



EN
29/09/2025

Underlying

RDGLVIVOS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on VIVOS INC

 PRESS RELEASE
Free
RDGL VIVOS INC

Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeut...

Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics Kennewick, WA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) today announced enhanced cooperation with Exubrion Therapeutics to advance the use of targeted radioactive isotope technology for multiple indications in companion animals. The two companies have agreed to broaden their joint efforts in several key areas — including shared clinic relationships, licensing coordination, and manufacturing optimization. These initiatives build upon prior collaborations involving device classification, development...

October 29, 2025 1 EN
 PRESS RELEASE
Free
RDGL VIVOS INC

Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., ...

Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel® Richland, WA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced today that they have appointed Dr. John J. Smith, M.D., J.D., and his team at Hogan Lovells as the company’s lead regulatory advisors for its FDA Investigational Device Exemption (IDE) submission for RadioGel®. Dr. Smith, a board-certified diagnostic radiologist and former associate professor at Harvard Medical School, is widely recognized as one of the nation’s leading FDA regulatory consult...

October 27, 2025 1 EN
 PRESS RELEASE
Free
RDGL VIVOS INC

Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity i...

Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India Kennewick, WA, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The Vivos Board granted authorization to form a wholly owned corporate subsidiary in India. Vivos Inc filed for the name of Vivos Scientific India LLP. Vivos is completing the steps remaining to obtain formal approvals from the Indian government. “This demonstrates our long-term commitment to doing business in India and supports our long-term plan of establishing our first international manufacturing center for RadioGel and IsoPet, for ...

September 29, 2025 1 EN
 PRESS RELEASE
Free
RDGL VIVOS INC

Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity ...

Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India Kennewick, WA, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The Vivos Board granted authorization to form a wholly owned corporate subsidiary in India. Vivos Inc filed for the name of Vivos Scientific India LLP. Vivos is completing the steps remaining to obtain formal approvals from the Indian government. “This demonstrates our long-term commitment to doing business in India and supports our long-term plan of establishing our first international manufacturing center for RadioGel and IsoPet, for...

September 29, 2025 1 EN
 PRESS RELEASE
Free
RDGL VIVOS INC

Vivos Inc. Demonstrates Precision in Precision Radionuclide Therapy

Vivos Inc. Demonstrates Precision in Precision Radionuclide Therapy Kennewick, WA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced new data demonstrating the exceptional precision of its proprietary Precision Radionuclide Therapy (RadioGel® for human therapies and IsoPet® for veterinary applications) Advancing Targeted Cancer Therapies The therapeutic ratio is the amount of radiation delivered to a tumor compared to surrounding healthy tissue and is a critical measure of treatment precision. A high therapeutic ratio minimizes collateral damage while maximizing tumo...

September 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch